<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649687</url>
  </required_header>
  <id_info>
    <org_study_id>SB-VGH-201001</org_study_id>
    <nct_id>NCT01649687</nct_id>
  </id_info>
  <brief_title>Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells</brief_title>
  <official_title>Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Yang Ming University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Yang Ming University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to investigate the efficacy and safety of allogenous transplantation of
      adipose-derived mesenchyma stem cells in patients with cerebellar ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Safety evaluate through vital signs, the results of clinical lab tests and adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alterations in SARA score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positron emission tomography</measure>
    <time_frame>9 months</time_frame>
    <description>18F-FDG used for the assessment of glucose metabolism in the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance spectroscopy</measure>
    <time_frame>12 months</time_frame>
    <description>NAA/Cr,Cho/Cr,NAA/Cho ratios to reflect neuronal/cerebral white mater integrity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of language and swallowing functions</measure>
    <time_frame>12 months</time_frame>
    <description>changes in levels of severity: normal/slight/mild/moderate/severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of syncope</measure>
    <time_frame>12 months</time_frame>
    <description>Tilt table test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance test</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cerebellar Ataxia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells(MSC) treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic adult adipose-derived mesenchymal stem cells</intervention_name>
    <description>Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells</description>
    <arm_group_label>Mesenchymal stem cells(MSC) treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed of spinocerebellar ataxia 3 (SCA3) or multiple system
             atrophy-cerebellar (MSA-C).

          -  Subject's SARA score at 10~20 points.

          -  Ages between 20~70 years.

          -  Signed informed consent from the patient and/or guardian.

        Exclusion Criteria:

          -  Subjects enrolled in any other cell therapy studies within the past 30 days.

          -  Pregnancy test positive.

          -  Subjects deemed to be not suitable for the study by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Yang Ming University</investigator_affiliation>
    <investigator_full_name>Oscar Kuang-Sheng Lee</investigator_full_name>
    <investigator_title>Director of Stem Cell Research Centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

